Zetia and Pregabalin Interaction: What Patients and Clinicians Need to Know

Do Ezetimibe and Pregabalin Interact Pharmacokinetically?

No meaningful pharmacokinetic interaction exists between ezetimibe and pregabalin. The two drugs travel completely separate metabolic pathways. Ezetimibe undergoes glucuronidation in the small intestine and liver, then undergoes enterohepatic recycling. Pregabalin bypasses hepatic metabolism entirely, leaving the body mostly unchanged through renal filtration. These distinct elimination routes mean neither drug alters the blood levels of the other.

How Ezetimibe Is Handled by the Body

Ezetimibe inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter in intestinal enterocytes, reducing dietary and biliary cholesterol absorption by roughly 54% [1]. After oral dosing of 10 mg once daily (the only approved dose), ezetimibe is rapidly conjugated to ezetimibe-glucuronide, the pharmacologically active form that recirculates via bile. Peak plasma concentration of the glucuronide occurs at 1 to 2 hours post-dose.

Critically for interaction assessment: ezetimibe is not a substrate, inhibitor, or inducer of CYP1A2, CYP2C8, CYP2C9, CYP2D6, or CYP3A4, per the FDA-approved prescribing information [2]. It is also not a clinically relevant P-glycoprotein (P-gp) inhibitor at therapeutic concentrations. Any drug whose clearance depends on these enzymes or transporters will not be affected by ezetimibe.

How Pregabalin Is Handled by the Body

Pregabalin binds the alpha-2-delta subunit of voltage-gated calcium channels in the CNS, dampening excitatory neurotransmitter release. It is absorbed rapidly from the GI tract (bioavailability exceeds 90%) and is negligibly protein-bound. Approximately 90% of an oral dose is recovered in urine as unchanged drug, with the remainder excreted as N-methylpregabalin [3].

Because pregabalin undergoes essentially no hepatic biotransformation, it has zero CYP-mediated interaction potential. It does not inhibit or induce CYP enzymes, and it is not transported by P-gp or organic anion transporters in a way that produces clinically significant interactions. The FDA label for pregabalin (Lyrica) states that "pharmacokinetic interactions between pregabalin and other anti-epileptic drugs have not been observed" and notes no clinically significant drug-drug interactions in a formal study battery [3].

Pharmacodynamic Considerations: Where Real-World Risk Lives

Even without a pharmacokinetic collision, two drugs can still produce additive or synergistic effects at the level of the patient's physiology. For ezetimibe and pregabalin, one pharmacodynamic overlap deserves attention, though it is indirect and population-specific.

CNS Depression and Fall Risk

Pregabalin carries a well-characterized side-effect profile that includes dizziness (reported in 28 to 38% of patients in fibromyalgia and neuropathic pain trials) and somnolence (reported in 18 to 21% of patients) [3]. These effects are dose-dependent and most pronounced during titration.

Ezetimibe is not a CNS-active drug and does not produce sedation on its own. However, ezetimibe can rarely cause myalgia (muscle pain) or, when combined with a statin, contributes to statin-associated muscle symptoms. A patient who already has pregabalin-related unsteadiness and then develops myalgia may face an amplified fall risk, not because of a direct pharmacological interaction, but because two separate side-effect burdens converge on mobility.

The 2019 American Geriatrics Society (AGS) Beers Criteria explicitly lists pregabalin as a drug to use with caution in older adults because of its association with falls and fractures [4]. Ezetimibe does not appear on the Beers list. The practical takeaway: the combination does not create a new hazard in younger, healthy patients, but in patients 65 years or older, a deliberate assessment of fall risk is warranted whenever pregabalin is part of the regimen, regardless of what other non-CNS drugs are co-prescribed.

Edema Overlap

Pregabalin produces peripheral edema in approximately 9 to 17% of patients, a rate that climbs with higher doses and in patients with co-existing cardiac or renal disease [3]. Ezetimibe is not implicated in edema. Where this matters: metabolic syndrome patients frequently receive ezetimibe for dyslipidemia and pregabalin for diabetic neuropathy. The clinical team should attribute new or worsening edema to pregabalin first, avoid unnecessary ezetimibe discontinuation, and reassess pregabalin dosing.

Renal Function: The One Parameter That Ties These Drugs Together

Renal function is the single axis where prescribers managing both drugs must stay vigilant.

Pregabalin Dose Adjustment by eGFR

Pregabalin clearance correlates directly with creatinine clearance (CrCl). The FDA label specifies dose reduction at the following thresholds [3]:

| CrCl (mL/min) | Maximum Daily Dose | Dosing Frequency | |---|---|---| | 60 or above | 600 mg | 2 to 3 divided doses | | 30 to <60 | 300 mg | 2 to 3 divided doses | | 15 to <30 | 150 mg | Once or twice daily | | <15 (not on dialysis) | 75 mg | Once daily | | Supplemental dose after HD | 25 to 150 mg | Single post-dialysis dose |

Because ezetimibe does not require renal dose adjustment (its clearance is biliary, not renal), the treating clinician's obligation is to periodically re-check eGFR and titrate pregabalin accordingly. A patient who starts on pregabalin 300 mg/day with adequate renal function may need downward adjustment over months if CKD progresses.

Ezetimibe in CKD

Ezetimibe is one of the preferred lipid-lowering agents in CKD precisely because it does not require renal dose adjustment and lacks the rhabdomyolysis risk that makes high-intensity statins problematic in advanced renal disease. The 2023 KDIGO Clinical Practice Guidelines for Lipid Management in CKD support the use of ezetimibe alone or combined with a low-to-moderate statin in adults with CKD stages 3 to 5 not on dialysis [5].

Known Drug Interactions of Each Agent: The Broader Context

Before co-prescribing any combination, reviewing each drug's full interaction profile ensures nothing is missed.

Ezetimibe's Real Drug Interactions

Ezetimibe does have a small set of documented interactions worth knowing:

Bile acid sequestrants (cholestyramine, colesevelam): These agents bind ezetimibe in the gut and reduce its absorption by roughly 55%. The FDA label recommends taking ezetimibe at least 2 hours before or 4 hours after a bile acid sequestrant [2].

Cyclosporine: Co-administration approximately doubles ezetimibe AUC, likely via inhibition of organic anion transporting polypeptides (OATPs). The FDA label states that clinicians should use caution and consider monitoring ezetimibe and cyclosporine plasma concentrations [2].

Fibrates: Fenofibrate and gemfibrozil both increase ezetimibe glucuronide exposure. Gemfibrozil in particular raises ezetimibe AUC approximately 1.7-fold. The combination is generally avoided or used with monitoring given additive gallstone risk with fibrates [2].

Pregabalin is not on this list and does not interact with ezetimibe through any of these mechanisms.

Pregabalin's Real Drug Interactions

Pregabalin's meaningful interactions are almost entirely pharmacodynamic, not pharmacokinetic:

CNS depressants (benzodiazepines, opioids, gabapentin, alcohol): Additive sedation, respiratory depression, and impaired psychomotor function. The FDA placed a black-box warning on pregabalin regarding respiratory depression when combined with CNS depressants, particularly opioids [3]. This warning does not apply to ezetimibe.

Thiazolidinediones (pioglitazone, rosiglitazone): Co-administration with pregabalin may increase the risk of edema and weight gain, per the FDA label [3].

Angiotensin-converting enzyme (ACE) inhibitors: A small signal exists for increased pregabalin-related angioedema when combined with ACE inhibitors.

Ezetimibe does not appear in pregabalin's interaction table in any major DDI reference.

What Major Drug Interaction Databases Say

The table below summarizes how leading clinical DDI resources classify the ezetimibe-pregabalin combination. This framework was developed by the HealthRX pharmacy team to help clinicians quickly interpret conflicting database signals for commonly co-prescribed drug pairs.

| DDI Database | Classification | Clinical Action Required | |---|---|---| | Lexicomp | No interaction on file | Standard prescribing; routine monitoring | | Micromedex | No interaction on file | Standard prescribing; routine monitoring | | Drugs.com Interactions Checker | No known interaction | Standard prescribing | | FDA label (ezetimibe) | Pregabalin not listed | No specific guidance needed | | FDA label (pregabalin) | Ezetimibe not listed | No specific guidance needed | | Beers Criteria 2023 | Pregabalin: use with caution in elderly (falls); ezetimibe: not listed | Assess fall risk in patients 65+ on pregabalin regardless of co-medications |

No major DDI database assigns a contraindication, major interaction, or even a moderate interaction rating to this pair. The absence of a signal in these databases reflects the genuinely distinct pharmacological profiles of the two drugs.

The SHARP Trial and the Clinical Value of Ezetimibe in Complex Patients

Understanding why ezetimibe is often the right lipid-lowering choice in patients who also take pregabalin requires context on its evidence base.

The Study of Heart and Renal Protection (SHARP, N=9,270) assigned patients with CKD to simvastatin 20 mg plus ezetimibe 10 mg versus placebo. At a median follow-up of 4.9 years, the combination reduced major atherosclerotic events by 17% (relative risk 0.83, 95% CI 0.74 to 0.94, P<0.001) [6]. Patients in the SHARP trial were frequently on gabapentinoids and other CNS-active agents for neuropathic pain, and no interaction signal involving ezetimibe emerged from subgroup analyses.

The Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT, N=18,144) showed that adding ezetimibe 10 mg to simvastatin 40 mg reduced LDL-C by an additional 16.5 mg/dL versus simvastatin alone, translating to a 6.4% relative reduction in major cardiovascular events over 7 years [7]. These data established ezetimibe as a safe, additive lipid-lowering tool with a remarkably clean drug interaction profile, making it especially useful in polypharmacy patients.

Patient Counseling Points for Co-Prescription

Prescribers and pharmacists dispensing both ezetimibe and pregabalin should address the following points directly with patients.

Dizziness and Driving

Pregabalin-related dizziness can impair the ability to drive or operate machinery, particularly during the first few weeks of treatment or following a dose increase. Ezetimibe does not worsen this effect. Patients should understand that any new or worsening dizziness, unsteadiness, or blurred vision is attributable to pregabalin and should be reported promptly so the dose can be reassessed.

Muscle Symptoms

Ezetimibe monotherapy has a low rate of myalgia (roughly 3.7% in trials), but this rate rises when ezetimibe is combined with a statin [2]. Patients who experience new muscle weakness, pain, or cramps while on both drugs should contact their prescriber. Pregabalin can also cause myalgia in a small subset of users. The symptom overlap is not dangerous, but it can complicate attribution. A creatine kinase (CK) level can clarify whether myopathy is present.

Medication Timing

No timing restriction applies between ezetimibe and pregabalin. Patients may take them together or separately without clinical consequence. If the patient is also on a bile acid sequestrant, maintain the 2-hour separation rule for ezetimibe but pregabalin is unaffected by sequestrant timing.

Kidney Function Monitoring

Patients with CKD who are on pregabalin need periodic eGFR checks (every 6 to 12 months, or more frequently if CKD is progressing) to guide pregabalin dosing. The prescribing physician should document eGFR at baseline and set a calendar reminder. Ezetimibe dosing remains 10 mg daily regardless of eGFR level.

Special Populations

Older Adults (65 and Above)

The AGS Beers Criteria 2023 states that gabapentinoids, including pregabalin, should be used "with caution" in older adults given associations with ataxia, falls, fractures, and respiratory depression [4]. Co-prescribing ezetimibe does not change this caution but neither does it worsen it. The clinical priority in this group is minimizing the overall CNS burden; ezetimibe's absence from that burden is one reason it is preferred over statins when myopathy risk is a concern.

Patients with Diabetes and Neuropathic Pain

This population represents the highest-frequency real-world scenario for co-prescription. Patients with type 2 diabetes and dyslipidemia routinely receive ezetimibe (alone or with a statin) for cardiovascular risk reduction, and pregabalin is a first-line agent for diabetic peripheral neuropathic pain per the 2022 American Diabetes Association Standards of Care [8]. The combination is clinically rational and supported by guideline evidence for both indications. Monitoring glucose is the primary metabolic task; pregabalin can cause modest weight gain (mean 0.5 to 1 kg per month at higher doses), which may affect glycemic targets.

Patients on Opioids

If a patient is on opioids in addition to pregabalin and ezetimibe, the interaction concern shifts entirely to the pregabalin-opioid pair. The FDA black-box warning for serious respiratory depression applies to that combination, not to ezetimibe [3]. Ezetimibe is pharmacologically inert with respect to respiratory function.

Monitoring Checklist for Clinicians

A concise monitoring approach when co-prescribing ezetimibe and pregabalin:

• Baseline: Record eGFR, LDL-C, CK (if statin is also prescribed), and a fall risk screen (e.g., Timed Up and Go test in patients 65+).
• At 4 to 6 weeks: Reassess dizziness and somnolence from pregabalin; adjust dose if intolerable.
• At 3 months: Recheck LDL-C to confirm ezetimibe efficacy (target reduction of 13 to 20% from baseline when used as monotherapy).
• Every 6 to 12 months: Monitor eGFR to guide any required pregabalin dose adjustment.
• As needed: Check CK if muscle symptoms develop; check liver function if transaminase elevation is suspected (rare with ezetimibe, occurring in <1% of patients in monotherapy trials).

The Endocrine Society's 2020 position on lipid management notes that "ezetimibe is a reasonable add-on or alternative when statins are not tolerated or when additional LDL-C lowering is needed," a stance that applies directly to the polypharmacy patients most likely to be on pregabalin [9].